SCI时时刷

search
+
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody
Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal anti...
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
This study found that continuing monthly treatment with ZOL for four years significantly decreased the risk of PBD at year...
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) manage...
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor...
CD56 expression predicts response to Daratumumab-based regimens
CD56 expression predicts response to Daratumumab-based regimens
Daratumumab (Dara) and Isatuximab (Isa) are monoclonal antibodies that target CD38, a glycoprotein hi...
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Competing interests A.A. reports research funding from Abbvi, Adaptive Bio...
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Induction therapy followed by autologous stem cell transplantation (ASCT) is standard of care for you...
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
The transcription factor CCAAT/enhancer-binding protein-alpha(CEBPA) is a critical mediator of granul...
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death
Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Canc...
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms
In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the Internatio...
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
The goal of achieving sustained treatment-free remission (TFR) after discontinuation of tyrosine kina...
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myelo...
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limite...
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Randomized controlled trials (RCTs) are the gold standard to establish the benefit-risk ratio of novel drugs. However, the...
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice week...
Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis
Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis
Telomere attrition and epigenetic modifications stand out as prominent molecular characteristics of aging-related biologic...
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, an...
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of My...
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Deeper responses are associated with improved survival in patients being treated for myeloma. However, the sensitivity of ...
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Allogeneic hematopoietic stem cell transplant (AHSCT) is at present the only treatment modality in my...
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT...
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
Anti-CD19/CD3 bispecific T-cell engagers (CD19BiTE) have shown promising efficacy in patients with re...
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
Overall survival has developed well in hematological malignancies but among the main entities, 5-year...
Large differencies in age-specific survival in multiple myeloma in the nordic countries
Large differencies in age-specific survival in multiple myeloma in the nordic countries
Treatment of multiple myeloma (MM), like most hematological neoplasms, has developed fast and complet...
Regulation of HOX gene expression in AML
Regulation of HOX gene expression in AML
As key developmental regulators, HOX cluster genes have varied and context-specific roles in normal and malignant hematopo...
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma
Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients wi...
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
B-cell maturation antigen (BCMA)-directed T cell therapies such as idecabtagene vicleucel (ide-cel), ...
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in pat...
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.Article  PubMed  ...
阅读更多
format_indent_increase